{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:14:27Z","timestamp":1794485667579,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF Challenge Award"],"award-info":[{"award-number":["PCF Challenge Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022896","name":"ANZUP","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022896","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["BC Trainee Award"],"award-info":[{"award-number":["BC Trainee Award"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC Investigator Fellowship #1177837"],"award-info":[{"award-number":["NHMRC Investigator Fellowship #1177837"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["NHMRC Practitioner Fellowship APP1102604"],"award-info":[{"award-number":["NHMRC Practitioner Fellowship APP1102604"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41591-025-03704-9","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:04:51Z","timestamp":1748322291000},"page":"2722-2736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Lutetium-177\u2013PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-680X","authenticated-orcid":false,"given":"Edmond M.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7647-6940","authenticated-orcid":false,"given":"Sarah W. S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-885X","authenticated-orcid":false,"given":"Sofie H.","family":"Tolmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-7384","authenticated-orcid":false,"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Subhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7373-7567","authenticated-orcid":false,"given":"Gr\u00e1inne","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Annala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-8374","authenticated-orcid":false,"given":"Cameron","family":"Herberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8622-159X","authenticated-orcid":false,"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7350-5622","authenticated-orcid":false,"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-0329","authenticated-orcid":false,"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Akhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Alipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattakorn","family":"Dhiantravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Gedye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex D.","family":"Guminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad B.","family":"Haskali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"McJannett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Moodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Pokorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakher","family":"Ramdave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind S.","family":"Ravi Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Roselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Saghebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Schembri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thean Hsiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ping","family":"Thang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Violet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"3704_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman, M. S. et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397, 797\u2013804 (2021).","journal-title":"Lancet"},{"key":"3704_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2023","unstructured":"Hofman, M. S. et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 25, 99\u2013107 (2023).","journal-title":"Lancet Oncol."},{"key":"3704_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3704_CR4","first-page":"1","volume":"42","author":"A Gafita","year":"2022","unstructured":"Gafita, A. et al. Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond. Am. Soc. Clin. Oncol. Educ. Book 42, 1\u201317 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3704_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 23, 1389\u20131397 (2022).","journal-title":"Lancet Oncol."},{"key":"3704_CR6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo, P. H. et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial). Radiology 312, e233460 (2024).","journal-title":"Radiology"},{"key":"3704_CR7","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang, S. P. et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy. Eur. Urol. Oncol. 2, 670\u2013676 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"3704_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3704_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471\u2013478 (2019).","journal-title":"JAMA Oncol."},{"key":"3704_CR10","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","volume":"28","author":"M Hussain","year":"2022","unstructured":"Hussain, M. et al. Tumor genomic testing for >4000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib). Clin. Cancer Res. 28, 1518\u20131530 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054497","volume":"12","author":"EM Kwan","year":"2022","unstructured":"Kwan, E. M., Wyatt, A. W. & Chi, K. N. Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: opportunities for integration and pitfalls to interpretation. Front. Oncol. 12, 1054497 (2022).","journal-title":"Front. Oncol."},{"key":"3704_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts, C. et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608, 199\u2013208 (2022).","journal-title":"Nature"},{"key":"3704_CR13","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/1538-7445.AM2023-5614","volume":"83","author":"H Fettke","year":"2023","unstructured":"Fettke, H. et al. Abstract 5614: Genomic aberrations in circulating tumor DNA (ctDNA) and clinical outcomes from [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 83, 5614 (2023).","journal-title":"Cancer Res."},{"key":"3704_CR14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","volume":"53","author":"J Vanwelkenhuyzen","year":"2023","unstructured":"Vanwelkenhuyzen, J. et al. AR and PI3K genomic profiling of cell-free DNA can identify poor responders to lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer. Eur. Urol. Open Sci. 53, 63\u201366 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"3704_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker, M. et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617. Eur. Urol. Open Sci. 57, 30\u201336 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"3704_CR16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","volume":"64","author":"O Sartor","year":"2023","unstructured":"Sartor, O. et al. Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers. J. Nucl. Med. 64, 1721\u20131725 (2023).","journal-title":"J. Nucl. Med."},{"key":"3704_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00634","volume":"8","author":"R Raychaudhuri","year":"2024","unstructured":"Raychaudhuri, R. et al. Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study. JCO Precis. Oncol. 8, e2300634 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"3704_CR18","doi-asserted-by":"publisher","first-page":"TPS5110","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5110","volume":"40","author":"KN Chi","year":"2022","unstructured":"Chi, K. N. et al. CCTG PR21: a randomized phase II study of [177Lu]Lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997). J. Clin. Oncol. 40, TPS5110 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"3704_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15, 1828 (2024).","journal-title":"Nat. Commun."},{"key":"3704_CR21","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.CCR-22-2998","volume":"29","author":"SH Tolmeijer","year":"2023","unstructured":"Tolmeijer, S. H. et al. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 29, 2835\u20132844 (2023).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122109","volume":"3","author":"AD Choudhury","year":"2018","unstructured":"Choudhury, A. D. et al. Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight 3, e122109 (2018).","journal-title":"JCI Insight"},{"key":"3704_CR23","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1158\/1078-0432.CCR-21-1625","volume":"27","author":"M Annala","year":"2021","unstructured":"Annala, M. et al. Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition. Clin. Cancer Res. 27, 4610\u20134623 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444\u2013457 (2018).","journal-title":"Cancer Discov."},{"key":"3704_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.annonc.2021.03.205","volume":"32","author":"M Annala","year":"2021","unstructured":"Annala, M. et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial. Ann. Oncol. 32, 896\u2013905 (2021).","journal-title":"Ann. Oncol."},{"key":"3704_CR26","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus, J. et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur. J. Nucl. Med. Mol. Imaging 47, 2322\u20132327 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3704_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cell.2018.10.019","volume":"175","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 175, 889 (2018).","journal-title":"Cell"},{"key":"3704_CR28","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3704_CR29","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-21-4272","volume":"28","author":"G Chakraborty","year":"2022","unstructured":"Chakraborty, G. et al. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer. Clin. Cancer Res. 28, 3603\u20133617 (2022).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR30","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","volume":"25","author":"B De Laere","year":"2019","unstructured":"De Laere, B. et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 25, 1766\u20131773 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR31","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaoncol.2019.0869","volume":"5","author":"B De Laere","year":"2019","unstructured":"De Laere, B. et al. Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer. JAMA Oncol. 5, 1060\u20131062 (2019).","journal-title":"JAMA Oncol."},{"key":"3704_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.eururo.2020.03.044","volume":"78","author":"H Fettke","year":"2020","unstructured":"Fettke, H. et al. Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multianalyte liquid biopsy assay for metastatic prostate cancer. Eur. Urol. 78, 173\u2013180 (2020).","journal-title":"Eur. Urol."},{"key":"3704_CR33","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1200\/PO.20.00424","volume":"5","author":"EM Kwan","year":"2021","unstructured":"Kwan, E. M. et al. Plasma cell-free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer. JCO Precis. Oncol. 5, 622\u2013637 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"3704_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/PO.20.00084","volume":"4","author":"SH Tolmeijer","year":"2020","unstructured":"Tolmeijer, S. H. et al. A systematic review and meta-analysis on the predictive value of cell-free DNA-based androgen receptor copy number gain in patients with castration-resistant prostate cancer. JCO Precis. Oncol. 4, 714\u2013729 (2020).","journal-title":"JCO Precis. Oncol."},{"key":"3704_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353\u2013357 (2015).","journal-title":"Nature"},{"key":"3704_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner, E. W. et al. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat. Cancer 5, 114\u2013130 (2024).","journal-title":"Nat. Cancer"},{"key":"3704_CR37","doi-asserted-by":"publisher","first-page":"283ra54","DOI":"10.1126\/scitranslmed.aaa1408","volume":"7","author":"N McGranahan","year":"2015","unstructured":"McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).","journal-title":"Sci. Transl. Med."},{"key":"3704_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.trecan.2021.06.001","volume":"7","author":"C Herberts","year":"2021","unstructured":"Herberts, C. & Wyatt, A. W. Technical and biological constraints on ctDNA-based genotyping. Trends Cancer Res. 7, 995\u20131009 (2021).","journal-title":"Trends Cancer Res."},{"key":"3704_CR39","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506\u20132518 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3704_CR40","doi-asserted-by":"publisher","first-page":"11626","DOI":"10.3390\/ijms241411626","volume":"24","author":"A Jang","year":"2023","unstructured":"Jang, A., Kendi, A. T., Johnson, G. B., Halfdanarson, T. R. & Sartor, O. Targeted alpha-particle therapy: a review of current trials. Int. J. Mol. Sci. 24, 11626 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"3704_CR41","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","volume":"65","author":"JP Buteau","year":"2024","unstructured":"Buteau, J. P. et al. Clinical trial protocol for VIOLET: a single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [161Tb]Tb-PSMA-I&T. J. Nucl. Med. 65, 1231\u20131238 (2024).","journal-title":"J. Nucl. Med."},{"key":"3704_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","volume":"80","author":"S Sumanasuriya","year":"2021","unstructured":"Sumanasuriya, S. et al. Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA. Eur. Urol. 80, 243\u2013253 (2021).","journal-title":"Eur. Urol."},{"key":"3704_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett, L. et al. [Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 25, 563\u2013571 (2024).","journal-title":"Lancet Oncol."},{"key":"3704_CR44","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","volume":"20","author":"DJ Khalaf","year":"2019","unstructured":"Khalaf, D. J. et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 20, 1730\u20131739 (2019).","journal-title":"Lancet Oncol."},{"key":"3704_CR45","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht, M. K. et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat. Cancer 4, 699\u2013715 (2023).","journal-title":"Nat. Cancer"},{"key":"3704_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.euo.2024.03.009","volume":"8","author":"A Gafita","year":"2024","unstructured":"Gafita, A. et al. Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial. Eur. Urol. Oncol. 8, 21\u201328 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"3704_CR47","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","volume":"25","author":"M Abdel-Wahab","year":"2024","unstructured":"Abdel-Wahab, M. et al. Radiotherapy and theranostics: a Lancet Oncology Commission. Lancet Oncol. 25, e545\u2013e580 (2024).","journal-title":"Lancet Oncol."},{"key":"3704_CR48","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky, H. et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin. Cancer Res. 27, 3094\u20133105 (2021).","journal-title":"Clin. Cancer Res."},{"key":"3704_CR49","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura, Y. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat. Med. 26, 1859\u20131864 (2020).","journal-title":"Nat. Med."},{"key":"3704_CR50","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1200\/JCO.2023.41.6_suppl.218","volume":"41","author":"EM Kwan","year":"2023","unstructured":"Kwan, E. M. et al. Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study. J. Clin. Oncol. 41, 218 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR51","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee, J. et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat. Med. 28, 2353\u20132363 (2022).","journal-title":"Nat. Med."},{"key":"3704_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis, C. et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J. Exp. Med. 215, 159\u2013175 (2018).","journal-title":"J. Exp. Med."},{"key":"3704_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euo.2018.02.006","volume":"1","author":"P Rescigno","year":"2018","unstructured":"Rescigno, P. et al. Docetaxel treatment in PTEN- and ERG-aberrant metastatic prostate cancers. Eur. Urol. Oncol. 1, 71\u201377 (2018).","journal-title":"Eur. Urol. Oncol."},{"key":"3704_CR54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/djaa095","volume":"113","author":"KL Pitter","year":"2021","unstructured":"Pitter, K. L. et al. Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy. J. Natl Cancer Inst. 113, 266\u2013273 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"3704_CR55","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1200\/JCO.23.02105","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah, J. et al. Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis. J. Clin. Oncol. 42, 1687\u20131698 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope, T. A. et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J. Nucl. Med. 58, 81\u201384 (2017).","journal-title":"J. Nucl. Med."},{"key":"3704_CR57","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2018","unstructured":"Emmett, L. et al. Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J. Nucl. Med. 60, 950\u2013954 (2018).","journal-title":"J. Nucl. Med."},{"key":"3704_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2024","unstructured":"Bakht, M. K. & Beltran, H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat. Rev. Urol. 22, 26\u201345 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"3704_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcad045","volume":"5","author":"A Zivanovic","year":"2023","unstructured":"Zivanovic, A. et al. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. NAR Cancer 5, zcad045 (2023).","journal-title":"NAR Cancer"},{"key":"3704_CR60","doi-asserted-by":"publisher","first-page":"TPS5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). J. Clin. Oncol. 39, TPS5087 (2021).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR61","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131\u2013142 (2021).","journal-title":"Lancet"},{"key":"3704_CR62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","volume":"78","author":"B Nguyen","year":"2020","unstructured":"Nguyen, B. et al. Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics. Eur. Urol. 78, 671\u2013679 (2020).","journal-title":"Eur. Urol."},{"key":"3704_CR63","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","volume":"11","author":"S Carreira","year":"2021","unstructured":"Carreira, S. et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov. 11, 2812\u20132827 (2021).","journal-title":"Cancer Discov."},{"key":"3704_CR64","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates, J. T. et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 11, 2436\u20132445 (2021).","journal-title":"Cancer Discov."},{"key":"3704_CR65","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2967\/jnumed.119.236414","volume":"61","author":"J Violet","year":"2020","unstructured":"Violet, J. et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J. Nucl. Med. 61, 857\u2013865 (2020).","journal-title":"J. Nucl. Med."},{"key":"3704_CR66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"3704_CR67","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/0008-5472.CAN-24-2052","volume":"85","author":"J Sipola","year":"2025","unstructured":"Sipola, J. et al. Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer. Cancer Res. 85, 791\u2013807 (2025).","journal-title":"Cancer Res."},{"key":"3704_CR68","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/j.clgc.2021.01.008","volume":"19","author":"A Iravani","year":"2021","unstructured":"Iravani, A. et al. Molecular imaging of neuroendocrine differentiation of prostate cancer: a case series. Clin. Genitourin. Cancer 19, e200\u2013e205 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"key":"3704_CR69","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","volume":"40","author":"S Sandhu","year":"2022","unstructured":"Sandhu, S. et al. PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 40, 5017 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR70","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad, A. A. et al. Sequential [Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 25, 1267\u20131276 (2024).","journal-title":"Lancet Oncol."},{"key":"3704_CR71","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa, S. T. et al. PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 41, TPS5116 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3704_CR72","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar, E. et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight 8, e162907 (2023).","journal-title":"JCI Insight"},{"key":"3704_CR73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.14876","volume":"124","author":"MS Hofman","year":"2019","unstructured":"Hofman, M. S. et al. TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 124, 5\u201313 (2019).","journal-title":"BJU Int."},{"key":"3704_CR74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10\u201312 (2011).","journal-title":"EMBnet J."},{"key":"3704_CR75","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"3704_CR76","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/bioinformatics\/btz033","volume":"35","author":"LE Mose","year":"2019","unstructured":"Mose, L. E., Perou, C. M. & Parker, J. S. Improved indel detection in DNA and RNA via realignment with ABRA2. Bioinformatics 35, 2966\u20132973 (2019).","journal-title":"Bioinformatics"},{"key":"3704_CR77","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/bioinformatics\/btu314","volume":"30","author":"GG Faust","year":"2014","unstructured":"Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics 30, 2503\u20132505 (2014).","journal-title":"Bioinformatics"},{"key":"3704_CR78","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."},{"key":"3704_CR79","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03704-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03704-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:47:04Z","timestamp":1757173624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03704-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3704"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03704-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.K. has consulted or served in an advisory role for Astellas Pharma, Janssen and Ipsen, received travel funding from Astellas Pharma, Pfizer, Ipsen and Roche, received honoraria from Janssen, Ipsen, Astellas Pharma and Research Review, and received research funding from Astellas Pharma (institutional) and AstraZeneca (institutional). L.E. has consulted or served in an advisory role for Noxopharm and Clarity Pharmaceuticals, participated in a speakers\u2019 bureau for Janssen Oncology, Mundipharma and Astellas Pharma, and received research funding from Noxopharm (institutional) and Novartis (institutional). S.S. has consulted or served in an advisory role for AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Skyline Diagnostics and AbbVie, received honoraria from Bristol-Myers Squibb (institutional), Merck (institutional), AstraZeneca (institutional) and Janssen (institutional), and received research funding from Amgen (institutional), AstraZeneca (institutional), Merck (institutional), Endocyte\/Advanced Accelerator Applications (institutional), Roche\/Genentech (institutional), Novartis (institutional), Pfizer (institutional) and Senhwa Biosciences (institutional). A.I. has consulted or served in an advisory role for Novartis, Lantheus, Curium, ITM, Bayer, Boston Scientific, Ambrx\/J&J (institutional), and received research funding from NIH (institutional), Novartis (institutional), SNMMI (institutional) and ACR (institutional). A.M.J. has consulted or served in an advisory role for Janssen Oncology, Ipsen, AstraZeneca, Sanofi, Pfizer, Novartis, Merck Serono, Eisai, IDEAYA Biosciences, IQvia, Bayer, Astellas Pharma, Grey Wolf Therapeutics, Medison and Starpharma, has a patent or received royalties with Cancer Therapeutic Methods, owns stock or holds ownership interests in Pricilium Therapeutics and Opthea, and receives research funding from Bristol-Myers Squibb (institutional), Janssen Oncology (institutional), Merck Sharpe & Dohme (institutional), Mayna Pharma (institutional), Roche\/Genentech (institutional), Bayer (institutional), Lilly (institutional), Pfizer (institutional), AstraZeneca (institutional) and Corvus Pharmaceuticals (institutional). R.J.F. consulted or served in an advisory role for AIQ Solutions, receives research funding from AIQ Solutions, and has an immediate family member employed by and owns stock in AIQ Solutions. A.M.S. has consulted or served in an advisory role for ImmunOs Therapeutics and Imagion Biosystems, has an institutional patent relating to antibodies to EGFR, HER2, PDGF-CC, FN-14, GM-CSF, EphA3, owns stock or holds ownership interests in Paracrine Therapeutics and Certis Therapeutics, and received research funding from Telix Pharmaceuticals (institutional), Curis (institutional), Isotopen Technologien (institutional), Adalta (institutional), Fusion Pharmaceuticals (institutional), AstraZeneca (institutional), EMD Serono (institutional), Cyclotek (institutional), AVID\/Lilly (institutional), Merck (institutional), Humanigen (institutional) and Antengene (institutional). M.R.S. has received research funding from Astellas Pharma (institutional), Bayer (institutional), Medivation (institutional), Pfizer (institutional), AstraZeneca (institutional), Bristol-Myers Squibb (institutional), Roche (institutional), Amgen (institutional), Merck Sharpe & Dohme (institutional), Tilray (institutional), BeiGene (institutional) and Novartis (institutional). M.A. is compensated for a leadership role in Fluivia and owns stock in Fluivia. S.H.T. has received honoraria from Bayer. I.D.D. is the unremunerated chair of ANZUP Cancer Trials Group, and has received research funding from Astellas Pharma (institutional), Pfizer (institutional), Roche\/Genentech (institutional), MSD Oncology (institutional), AstraZeneca (institutional), Janssen Oncology (institutional), Eisai (institutional), Bayer (institutional), Amgen (institutional), Bristol-Myers Squibb (institutional), Movember Foundation (institutional), Exelixis (institutional), Ipsen (institutional), Seagen (institutional) and ESSA (institutional). M.S.H. has consulted or served in an advisory role for Janssen, MSD and Novartis, received travel funding from Novartis and Debiopharm Group, and received research funding from Bayer (institutional), Novartis (institutional), Isotopia Molecular Imaging (institutional) and Debiopharm Group (institutional). A.A.A. has consulted or served in an advisory role for Astellas Pharma, Novartis, Janssen, Sanofi, AstraZeneca, Pfizer, Bristol-Myers Squibb, Tolmar, Telix Pharmaceuticals, Merck Sharpe & Dohme, Bayer, Ipsen, Merck Serono, Amgen, Noxopharma, Aculeus Therapeutics and Daiichi Sankyo, participated in a speakers\u2019 bureau for Astellas Pharma, Novartis, Amgen, Bayer, Janssen, Ipsen, Bristol-Myers Squibb and Merck Serono, received travel funding from Astellas Pharma, Sanofi, Merck Serono, Amgen, Janssen, Tolmar, Pfizer, Bayer and Hinova Pharmaceuticals, received honoraria from Janssen, Astellas Pharma, Novartis, Tolmar, Amgen, Pfizer, Bayer, Telix Pharmaceuticals, Bristol-Myers Squibb, Merck Serono, AstraZeneca, Sanofi, Ipsen, Merck Sharpe & Dohme, Noxopharm, Aculeus Therapeutics and Daiichi Sankyo, and received research funding Astellas Pharma (institutional), Merck Serono (institutional), Novartis (institutional), Pfizer (institutional), Bristol-Myers Squibb (institutional), Sanofi (institutional), AstraZeneca (institutional), GlaxoSmithKline (institutional), Aptevo Therapeutics (institutional), MedImmune (institutional), Bionomics (institutional), Synthorx (institutional), Astellas Pharma (institutional), Ipsen (institutional), Merck Serono (institutional), Lilly (institutional), Gilead Sciences (institutional), Exelixis (institutional), MSD (institutional) and Hinova Pharmaceuticals (institutional). A.W.W. has received honoraria from Janssen, Astellas Pharma, AstraZeneca, Merck, Bayer, Pfizer and EMD Serono, and received research funding from Promontory Therapeutics (institutional), ESSA Pharma (institutional) and Tyra Biosciences (institutional). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}